Opus Genetics (IRD) Cash from Financing Activities (2011 - 2026)

Opus Genetics (IRD) has 14 years of Cash from Financing Activities data on file, last reported at $27.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $27.6 million, up 34.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $57.2 million (up 156.58% YoY), and the FY2025 annual result was $50.0 million, up 1095.01% from the prior year.
• Cash from Financing Activities climbed to $27.6 million in Q1 2026 per IRD's latest filing, from $24.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $27.6 million in Q1 2026 and troughed at -$83000.0 in Q4 2024.
• A 5-year average of $6.3 million and a median of $1.6 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities surged 30125.0% in 2023, then plunged 102.3% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$12000.0 in 2022, then surged by 30125.0% to $3.6 million in 2023, then slumped by 102.3% to -$83000.0 in 2024, then surged by 29146.99% to $24.1 million in 2025, then advanced by 14.46% to $27.6 million in 2026.
• Business Quant data shows IRD's Cash from Financing Activities at $27.6 million in Q1 2026, $24.1 million in Q4 2025, and $4.5 million in Q3 2025.